Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 3/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.46 |
| ▸ | VNN1 | O95497 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10859843 | 0.82 | PDCD1 (0.53) | PDCD1CD274MAOA | |
| SCHEMBL534926 | 0.81 | FFAR1 (0.53) | SCN8ANOS1DPP7ERCC1ERCC4 | |
| SCHEMBL3266433 | 0.81 | SCN8A (0.65) | SCN8ANOS1DPP7ERCC1ERCC4 | |
| SCHEMBL10874778 | 0.81 | SCN8A (0.61) | SCN8ANOS1DPP7ERCC1ERCC4 | |
| SCHEMBL11922712 | 0.80 | SCN8A (0.64) | SCN8ANOS1DPP7MAOA | |
| SCHEMBL2772974 | 0.80 | SCN8A (0.64) | SCN8ANOS1DPP7PDCD1CD274 | |
| SCHEMBL409441 | 0.79 | SCN8A (0.56) | SCN8ANOS1DPP7ERCC1ERCC4 | |
| SCHEMBL509459 | 0.79 | LOXL2 (0.57) | SCN8ANOS1PDCD1CD274CNR1 | |
| SCHEMBL2774523 | 0.78 | FFAR1 (0.52) | SCN8ANOS1DPP7ERCC1ERCC4 | |
| SCHEMBL320197 | 0.77 | HRH3 (0.49) | ERCC1ERCC4CNR1MEP1AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837624-B1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-9676736-B2 | 4-substituent-2-hydroxylmorpholine-3-one and preparation method thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| EP-2837624-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2015-02-18 | — | — | EP | disclosed |
| CN-101970420-B | Oxadiazole derivatives | MERCK SERONO SA | 2014-09-24 | — | — | CN | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414342-A1 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | SCN8A 3723/4885NOS1 661/4885DPP7 3851/4885 |
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | OPRK1, HTR3C, HTR3A | SCN8A 916/4885NOS1 2039/4885DPP7 652/4885 |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | SCN8A 2544/4885NOS1 386/4885DPP7 1046/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | SCN8A 2544/4885NOS1 386/4885DPP7 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.